Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13970183.ece/ALTERNATES/schema-16_9/doc7krubfc8cn61apcrqic3.jpg)
Novo Nordisk has concluded a phase III study, dubbed Onwards 2, of once-weekly insulin icodec, the company has announced in a Thursday press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.